Clinical Trials Currently Recruiting Patients

Targeted Therapeutics for Cancer and Ophthalmology

TRC105
  • Recruiting
  • Recruiting
  • Recruiting
  • Ongoing, not recruiting
  • Recruiting
  • Recruiting
  • Recruiting
  • Recruiting
  • Enrolling by invitiation

TUMOR TYPE

  • Advanced Renal Cell Cancer
  • Advanced Soft Tissue Sarcoma
  • Hepatocellular Carcinoma
  • Recurrent Glioblastoma
  • Non-Squamous Cell Lung Cancer
  • Breast Cancer
  • Hepatocellular Carcinoma
  • Gestational trophoblastic neoplasia
  • Choriocarcinoma

STUDY

  • A Randomized Phase 2 Trial of Axitinib and TRC105 versus Axitinib Alone (including a lead-in Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma
  • A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
  • An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)
  • A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer
  • Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme
  • A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer
  • Sorafenib and TRC105 in Hepatocellular Cancer
  • A Phase 2A Study of TRC105 (With Option to Add Standard Dose Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
  • Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma

PHASE

  • Ph 1b/2b randomized
  • Ph 1b/2a
  • Ph 1b/2a
  • Phase 2 randomized
  • Ph 1b
  • Ph 1/2
  • Ph 1b/2a
  • Phase 2
  • Phase 2

AGENT(S)

  • TRC105 + Inlyta® (axinitib)
  • TRC105 + Votrient® (Pazopanib)
  • TRC105 + Nexavar® (sorafenib)
  • TRC105 + Avastin® (bevacizumab)
  • TRC105 + Avastin® (bevacizumab) + Paclitaxel/Carboplatin
  • TRC105 + Femara® (letrozole) + Afinitor® (everolimus)
  • TRC105 + Nexavar® (sorafenib)
  • TRC105 or TRC105 + Avastin® (bevacizumab)
  • TRC105 + Avastin® (bevacizumab)
TRC102
  • Recruiting
  • Recruiting
  • Recruiting
  • Recruiting
  • Ongoing, not recruiting

TUMOR TYPE

  • Recurrent Glioblastoma
  • Non-squamous Non-small Cell Lung Cancer
  • Advanced Solid Tumors or Mesothelioma
  • Solid tumors (oral)
  • Solid tumors (IV)

STUDY

  • Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
  • A Phase I Study of Methoxyamine Combined With Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer
  • Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
  • TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
  • Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

PHASE

  • Phase 2
  • Phase 1
  • Ph 1b/2
  • Ph 1b
  • Ph 1

AGENT(S)

  • TRC102 + Temodar® (temozolomide)
  • TRC102 + Chemoradiation
  • TRC102 + Alimta® (pemetrexed) + cisplatin; TRC102 + Alimta
  • TRC102 + Temodar® (temozolomide)
  • TRC102 + Temodar® (temozolomide)